World's Best Scientists 2026 revealed!
Estella Matutes

Estella Matutes

D-Index & Metrics

Medicine

D-Index
88
Citations
24743
World Ranking
13294
National Ranking
186

Overview

Estella Matutes is affiliated with the University of Barcelona in Spain. Their research primarily centers on the field of Medicine, with a significant focus on several subfields including Pathology and Forensic Medicine, Genetics, Immunology, Oncology, and Molecular Biology.

The scientist's work covers diverse topics in hematology and oncology, notably Lymphoma Diagnosis and Treatment and Chronic Lymphocytic Leukemia Research. Other themes in their research include Immunodeficiency and Autoimmune Disorders, Immune Cell Function and Interaction, Cancer Immunotherapy and Biomarkers, Viral-associated cancers and disorders, and Glycosylation and Glycoproteins Research.

Frequent coauthors collaborating with Estella Matutes include:

  • Elías Campo
  • Sílvia Beà
  • Eva Giné
  • Armando López-Guillermo
  • Laura Magnano

The scientist has published extensively in several venues, with notable frequent publication outlets being:

  • Hematological Oncology
  • Leukemia & lymphoma / Leukemia and lymphoma
  • Blood
  • British Journal of Haematology
  • Blood Advances

Among the recent papers authored or coauthored by Estella Matutes are:

  • "Genetic and phenotypic attributes of splenic marginal zone lymphoma," 2021, Blood
  • "Clinico-biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation," 2021, British Journal of Haematology
  • "Diagnostic and therapeutic challenges in hairy cell leukemia-variant: where are we in 2021?", 2021, Expert Review of Hematology
  • "Unraveling the genetics of transformed splenic marginal zone lymphoma," 2023, Blood Advances
  • "Clinicobiological Characteristics and Outcomes of Patients with T-Cell Large Granular Lymphocytic Leukemia and Chronic Lymphoproliferative Disorder of Natural Killer Cells from a Single Institution," 2021, Cancers

Best Publications

  • Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL).

    Bene Mc;Castoldi G;Knapp W;Ludwig Wd

  • Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial

    D Catovsky;S Richards;E Matutes;D Oscier

  • Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia.

    E Matutes;V Brito-Babapulle;J Swansbury;J Ellis

  • Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b).

    Elisabeth J. Moreau;Estella Matutes;Roger P. A’Hern;Alison M. Morilla

  • Levels of expression of CD19 and CD20 in chronic B cell leukaemias.

    L Ginaldi;M De Martinis;E Matutes;N Farahat

  • A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia

    Maria Chiara Di Bernardo;Dalemari Crowther-Swanepoel;Peter Broderick;Emily Webb

  • High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H

    Claire E. Dearden;Estella Matutes;Bruno Cazin;Geir E. Tjønnfjord

  • A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease.

    Jenny Orchard;Richard Garand;Zadie Davis;Gavin Babbage

  • Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification

    Estella Matutes;Winfried F. Pickl;Mars van't Veer;Ricardo Morilla

  • Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H.

    Lia Ginaldi;T Massimo De Martinis;Estella Matutes;Nahla Farahat

  • Mutational Status of the TP53 Gene As a Predictor of Response and Survival in Patients With Chronic Lymphocytic Leukemia: Results From the LRF CLL4 Trial

    David Gonzalez;Pilar Martinez;Rachel Wade;Sarah Hockley

  • Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion

    Andy C. Rawstron;Martin R. Yuille;Julie Fuller;Matthew Cullen

  • Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria

    E Matutes;D Oscier;C Montalban;F Berger

  • Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis

    Monica Else;Claire E. Dearden;Estella Matutes;Juan Garcia-Talavera

  • Treatment of T-cell prolymphocytic leukemia with human CD52 antibody.

    R Pawson;M J Dyer;R Barge;E Matutes

  • The Reliability and Specificity of c-kit for the Diagnosis of Acute Myeloid Leukemias and Undifferentiated Leukemias

    M.C. Bene;M. Bernier;R.O. Casasnovas;G. Castoldi

  • Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk

    Dalemari Crowther-Swanepoel;Peter Broderick;Maria Chiara Di Bernardo;Sara E. Dobbins

  • Acute myeloid leukaemia with recurrent genetic abnormalities. .

    Brunning Rd;Matutes E;Harris Nl;Flandrin G

  • Adult T-cell leukaemia/lymphoma.

    E Matutes

  • The histopathology of splenic lymphoma with villous lymphocytes

    Peter G. Isaacson;Estella Matutes;Margaret Burke;Daniel Catovsky

Frequent Co-Authors

Daniel Catovsky
Daniel Catovsky Institute of Cancer Research
Andrew Wotherspoon
Andrew Wotherspoon Royal Marsden NHS Foundation Trust
David Oscier
David Oscier Royal Bournemouth Hospital
David Gonzalez
David Gonzalez University of California, San Diego
Gareth J. Morgan
Gareth J. Morgan Boston University
Martin J. S. Dyer
Martin J. S. Dyer University of Leicester
Richard S. Houlston
Richard S. Houlston Institute of Cancer Research
John M. Bennett
John M. Bennett University of Rochester Medical Center
James W. Vardiman
James W. Vardiman University of Chicago
Miguel A. Piris
Miguel A. Piris Instituto de Salud Carlos III

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative pathways in medicine and healthcare education can open up flexible options for students. Many are searching for programs with less traditional requirements. For example, those aiming to become Registered Nurses may benefit from an rn to bsn online with no clinicals—a valuable choice for individuals wanting to advance their credentials while working.

For those seeking to move quickly through advanced nursing programs, the shortest online dnp program can help expedite your journey to leadership roles in healthcare. Alternatively, students interested in a fast track to the highest nursing degree may consider a 1 year dnp program online, which prioritizes efficiency while maintaining academic rigor.

If you are starting your nursing career, the fastest lpn program provides an entry point to the profession with minimal delay. Choosing the right online degree or accelerated program can dramatically impact your career trajectory in medicine in the USA.

Best Scientists Citing Estella Matutes

Trending Scientists